UNSPSC 51263302: Butamoxane

This classification denotes an adrenergic antagonist with the molecular formula C13H19NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7725983GSD, chemically known as 1,4-benzodioxan-2-methylamine, n-butyl- but generally known as butamoxane, which bears US NIH Compound Identifier 20504. European Medicines Agency schedules Butamoxane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06002MIG.

UNSPSC 51263302 Butamoxane is a Commodity code that covers pharmaceutical and medical countermeasures, though recent state and local procurement activity under this code shows a significant mismatch with the code's nominal scope. The single recent opportunity in the record — Seminole County, Florida's IFB60459723LAS, posted June 30, 2026 — solicits naloxone and drug deactivation systems rather than butamoxane specifically. The county is procuring 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. This procurement reflects community health and emergency response priorities, with vendors required to include shipping and delivery costs in their proposals. Standard compliance requirements include drug-free workplace certification, E-Verify compliance, workers' compensation and commercial general liability insurance, a three-month probationary period, and adherence to federal regulations including the Clean Air Act and Federal Water Pollution Control Act, as the contract may be funded through FEMA.

The geographic activity is limited to Florida based on recent solicitation data. Seminole County, a mid-sized Florida county purchasing office, appears as the issuing body. The IFB response deadline was July 26, 2023 — a date that predates the current solicitation posting by nearly three years, suggesting either a data quality issue or a recurring annual procurement with an incorrectly recorded deadline. The code shows minimal recent state and local activity overall, and the single opportunity on file does not align with butamoxane procurement; this code merits watching for clarification of whether future opportunities will track naloxone and emergency-response pharmaceuticals or whether the tagging reflects a data classification error.